Selank

Also referred to as Selank peptide, Tuftsin analogue.

Status: Investigational. Selank is not an FDA-approved drug product in the United States. Like Semax, it is registered as a medicine in Russia, this time for anxiety-related use, under that country's own regulatory framework. That foreign registration reflects a separate regulator's own evidentiary process; it is not an FDA approval, it does not indicate FDA review of any kind, and it does not carry over to the United States. In the US, Selank is available, where it appears at all, only as a research chemical or unapproved compounded item whose legal status must be independently verified.

Selank is a synthetic peptide derived from tuftsin, an immune-signalling peptide fragment, and has been studied predominantly by Russian researchers for anxiety-related outcomes. It holds a Russian medicine registration for anxiety indications, a status specific to that country's regulatory process and not recognized by or transferable to the FDA. Patients typically raise Selank in the context of stress and anxiety rather than cognition broadly. The available human evidence remains concentrated in a small number of research groups and has not been independently replicated at scale under modern international trial standards.

What it is

Selank is a synthetic heptapeptide engineered from tuftsin, a naturally occurring immune-related peptide fragment, modified for greater metabolic stability. Unlike Semax, its research lineage sits closer to immune-signalling peptide chemistry than to the ACTH family, even though both are studied for central nervous system effects. It has been produced in Russia as a nasal formulation within that country's registered drug supply.

Why people ask about it

Patients usually encounter Selank while researching alternatives to conventional anxiolytic medications, often after reading online forum discussions describing it as a non-sedating option. Some ask specifically how it differs from Semax, assuming the two are interchangeable because both are Russian-developed peptides. Others want to understand what "anxiolytic-studied" actually means in terms of trial quality.

Proposed mechanism

Proposed mechanisms are drawn mainly from Russian animal and laboratory research and have not been confirmed in well-controlled human studies. Researchers have proposed effects on GABAergic signalling and on enkephalin-degrading enzyme activity, distinct from the neurotrophic-signalling hypotheses proposed for Semax. Some laboratory work also describes modest effects on inflammatory cytokine markers, consistent with its tuftsin-derived origin, though a link between that immune activity and any anxiety-related effect remains a proposed, unproven connection rather than an established pathway.

What researchers have studied

• Behavioral anxiety models in rodents
• Effects on enkephalin-degrading enzyme activity in laboratory studies
• Small Russian clinical studies in generalized anxiety symptom scales
• Immune marker changes linked to its tuftsin-derived structure
• Comparative laboratory work distinguishing Selank's mechanism from benzodiazepine-class anxiolytics

Human evidence

• Human studies are concentrated among a small number of Russian research groups, limiting independent verification.
• Reported trials generally involve small numbers of participants and inconsistent use of blinding and placebo control by current international standards.
• No large randomized controlled trials meeting FDA/ICH-comparable standards for anxiety outcomes were identified in the accessible literature.
• Applicability to a broader US patient population has not been established.

Preclinical evidence

• Rodent studies report reduced anxiety-like behavior on standard behavioral assays after Selank administration.
• Laboratory work describes changes in enkephalin-degrading enzyme activity.
• Animal and cell studies report modest changes in select inflammatory cytokine levels.
• Comparative animal studies describe a different behavioral and biochemical profile than benzodiazepine-class compounds.

What is not yet known

• Whether anxiety-related findings replicate under blinded, placebo-controlled trials meeting current international standards.
• Long-term safety profile with sustained use.
• How the proposed immune-linked mechanism, if real, relates clinically to any anxiety-related effect.
• Interaction risk with SSRIs, benzodiazepines, or other anxiolytic or psychiatric medications.
• Whether outcomes differ meaningfully by anxiety subtype or severity.
• Consistency of research-grade material available outside Russia's regulated supply chain.

Regulatory status and access

Compounding pharmacies have, in some cases, prepared Selank on a physician's order, but a compounded preparation is never equivalent to an FDA-approved medicine and its quality is not certified by that process. Whether compounding of Selank is currently permitted is subject to change and must be verified at the time, not assumed. Ask about current availability. A physician determines whether further discussion is appropriate only after an individual evaluation.

Known and potential risks

• US supply is unregulated by the FDA, so product identity, purity, and sterility cannot be assumed for research-chemical or compounded material.
• Long-term human safety data is limited outside the Russian clinical experience.
• Unknown interaction risk with existing anxiolytic, antidepressant, or psychiatric medications.
• Self-directed use for anxiety symptoms may delay evaluation for conditions that need a different, established treatment approach.
• Contaminated or mislabeled product is a documented risk in the unregulated peptide market broadly.

Cautions and who may not be a candidate

• Pregnancy and breastfeeding, where no safety data exist.
• Untreated or undiagnosed anxiety or mood symptoms that warrant direct clinical evaluation rather than self-directed peptide use.
• Concurrent use of benzodiazepines, SSRIs, or other centrally acting psychiatric medications without physician coordination.
• Active immune-mediated or autoimmune conditions, given its tuftsin-derived, immune-linked structure.
• History of substance-use disorder, where any centrally acting compound warrants added caution and oversight.

Questions to discuss with a physician

• What is Selank's current legal status for compounding or research use in the US?
• How does an immune-derived peptide differ in theoretical risk from Semax's ACTH-derived structure?
• Would this interact with medications I already take for anxiety or mood?
• What established, FDA-approved options should be considered first?
• What would ongoing monitoring look like if this were discussed further?
• How would we define and check for lack of benefit or unexpected harm?

Frequently asked questions

Is Selank FDA-approved?

No. Selank is not an FDA-approved drug product in the United States. It carries a Russian medicine registration for anxiety-related use, which is a decision made by a different country's regulator and does not transfer to or influence FDA status.

Does GOAL.MD sell Selank?

This page is educational only and is not an offer to sell or ship Selank. Ask about current availability, and any decision about appropriateness is made by a physician after individual evaluation.

Is Selank the same as Semax?

No. Both are Russian-developed synthetic peptides studied for central nervous system effects, but Selank is derived from tuftsin and studied mainly for anxiety-related outcomes, while Semax is derived from ACTH and studied mainly for attention and neurological recovery.

Can Selank replace an anxiety medication?

No. It is not an approved treatment for anxiety in the United States and should not be substituted for an evaluated, established treatment plan without a physician's direct involvement.

Is Selank sedating like a benzodiazepine?

Some animal and laboratory studies describe a different mechanism and behavioral profile than benzodiazepine-class drugs, but this has not been confirmed in large, well-controlled human trials, and no comparative safety claim can be made.

What does Selank's Russian registration actually mean?

It means Russia's national drug regulator reviewed evidence under its own process and authorized the product for use in that country for a specific indication. It says nothing about whether the FDA would reach the same conclusion, and it is not FDA approval.

Why does Selank affect immune markers?

It is derived from tuftsin, a peptide fragment studied in immune signalling, so some laboratory research describes changes in inflammatory markers. Whether that relates to any anxiety-related effect is a proposed and unconfirmed connection.

Is Selank safe to combine with SSRIs?

This has not been established, and interaction risk with SSRIs or other psychiatric medications is unknown. This should be raised directly with a physician rather than assumed to be safe.

Who should avoid discussing Selank?

Anyone who is pregnant or breastfeeding, has an undiagnosed mood or anxiety condition, has an active autoimmune condition, or has a history of substance-use disorder should raise these specifics with a physician before any such discussion.

What would a physician want to know before this conversation?

A full medication list, psychiatric history, and the specific symptom driving interest, so that appropriateness and any monitoring approach can be considered individually rather than generically.

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-13.